سعر انورو اليبيتا جهاز الاستنشاق 62.5 / 25ميكرو 30 جرعة مقننة 2025

Umeclidinium/vilanterol 62.5/25 mcg inhalation powder in the Ellipta inhaler (30 metered doses), a long-acting muscarinic antagonist plus long-acting beta2-agonist combination by GlaxoSmithKline, marketed in Egypt via Modern Pharma.

• Maintenance treatment of patients with chronic obstructive pulmonary disease (COPD)Population: AdultsDailyMed (U.S. National Library of Medicine)
• Maintenance bronchodilator treatment to relieve symptoms in adults with COPDPopulation: Adultselectronic medicines compendium (eMC)

• Most common adverse reactions (≥1% and more common than placebo): pharyngitis, sinusitis, lower respiratory tract infection, constipation, diarrhoea, pain in extremity, muscle spasms, neck pain and chest pain.International label, same product · DailyMed (U.S. National Library of Medicine)
• Postmarketing: palpitations; blurred vision, eye pain, glaucoma, increased intraocular pressure; hypersensitivity reactions; dysgeusia, tremor; anxiety; dysuria, urinary retention; dysphonia and paradoxical bronchospasm.International label, same product · DailyMed (U.S. National Library of Medicine)
• Most frequent: nasopharyngitis (about 9%). Common: urinary tract infection, sinusitis, pharyngitis, upper respiratory tract infection, headache, cough, oropharyngeal pain, constipation, dry mouth.International label, same product · electronic medicines compendium (eMC)

• Severe hypersensitivity to milk proteins, or hypersensitivity to umeclidinium, vilanterol or any excipient.International label, same product · DailyMed (U.S. National Library of Medicine)
• Use of a LABA without an inhaled corticosteroid in patients with asthma (not indicated for asthma).International label, same product · DailyMed (U.S. National Library of Medicine)
• Hypersensitivity to the active substances or to any excipient (lactose monohydrate, magnesium stearate).International label, same product · electronic medicines compendium (eMC)

• LABA monotherapy increases the risk of serious asthma-related events, including death; not indicated for asthma.International label, same product · DailyMed (U.S. National Library of Medicine)
• Do not start during rapidly deteriorating or potentially life-threatening episodes of COPD, and do not use for relief of acute symptoms; avoid excessive use and use with other LABA-containing medicines.International label, same product · DailyMed (U.S. National Library of Medicine)
• Paradoxical bronchospasm may occur; stop immediately and institute alternative therapy.International label, same product · DailyMed (U.S. National Library of Medicine)

• Strong CYP3A4 inhibitors (e.g. ketoconazole, clarithromycin, ritonavir)Increase systemic vilanterol exposure and may increase cardiovascular adverse effects; use caution or avoid.DailyMed (U.S. National Library of Medicine)
• Monoamine oxidase inhibitors, tricyclic antidepressants and drugs that prolong the QTc intervalMay potentiate the cardiovascular effects of vilanterol; use with extreme caution, including within 2 weeks of discontinuing such agents.DailyMed (U.S. National Library of Medicine)
• Beta-adrenergic blockersBlock the bronchodilator effect of vilanterol and may cause severe bronchospasm in COPD; use a cardioselective beta-blocker with caution if needed.DailyMed (U.S. National Library of Medicine)

• There are insufficient data on use in pregnant women to evaluate a drug-associated risk; animal studies showed no teratogenicity at inhaled doses well above the clinical dose. Beta-agonists may interfere with uterine contractility; use during labour only if the potential benefit justifies the risk.International label, same product · DailyMed (U.S. National Library of Medicine)
• Use in pregnancy only if the expected benefit to the mother justifies the potential risk to the fetus.International label, same product · electronic medicines compendium (eMC)
• No data on presence in human milk or effects on the breastfed infant; umeclidinium was detected in the plasma of rat pups of treated dams. Weigh the benefits of breastfeeding against the need for treatment.International label, same product · DailyMed (U.S. National Library of Medicine)

• Umeclidinium: Competitively inhibits the binding of acetylcholine to muscarinic receptors (M3) on airway smooth muscle, producing bronchodilation.
• Vilanterol: Stimulates intracellular adenylate cyclase, raising cyclic AMP and relaxing bronchial smooth muscle.